Citius Pharma Q1 2024 GAAP EPS $(0.06) Misses $0.13 Estimate
Portfolio Pulse from Benzinga Newsdesk
Citius Pharma (NASDAQ:CTXR) reported a Q1 2024 GAAP EPS of $(0.06), missing the analyst consensus estimate of $0.13 by 146.15 percent.

May 14, 2024 | 8:25 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Citius Pharma's Q1 2024 earnings report showed a significant miss against analyst expectations, with a GAAP EPS of $(0.06) compared to the forecasted $0.13.
Earnings misses, especially of this magnitude, typically result in negative short-term stock price movements as they reflect poorer financial health and performance than expected by the market. Investors and analysts had anticipated better results, and the significant miss may lead to a loss of confidence in the company's short-term prospects, potentially resulting in a decrease in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100